8-K: MetaVia Reports Q3 2025 Results, Advances Obesity & MASH Programs

MetaVia Inc. announced its third quarter 2025 financial results and provided a corporate update highlighting strong progress in its cardiometabolic disease pipeline, including promising Phase 1 data for its obesity drug DA-1726 and Phase 2a results for its MASH treatment vanoglipel.

Summary

• Reported third quarter 2025 financial results and a corporate strategic update.
• Dosed the first patient in the 8-week 48 mg MAD cohort of its Phase 1 clinical trial for DA-1726 for obesity, with top-line data expected by year-end 2025.
• DA-1726 Phase 1 data showed up to a 6.3% mean body-weight reduction and decreases in waist circumference of up to 3.9 inches, with effects sustained for two weeks after dosing.
• Newly reported pharmacokinetic (PK) data for DA-1726 showed linear, dose-proportional exposure and an approximately 80-hour half-life, supporting once-weekly dosing.
• Vanoglipel (DA-1241) Phase 2a results demonstrated meaningful reductions in liver fat, inflammation, and fibrosis for MASH.
• Cash position of $14.3 million at the end of Q3 2025 is expected to fund operations into 2026.
• Net loss for Q3 2025 was $3.4 million, or $0.14 per basic and diluted share, compared to $5.7 million, or $0.55 per share, for Q3 2024.
• Net loss for the nine months ended September 30, 2025, was $11.0 million, or $0.63 per share, compared to $22.4 million, or $3.24 per share, for the same period in 2024.

Sentiment

Score: 7

Explanation: The filing presents strong positive clinical trial data for both lead candidates, DA-1726 and vanoglipel, with DA-1726 showing 'best-in-class potential' and superior lipid-lowering efficacy compared to a competitor in preclinical models. Financial results show a significant reduction in net loss and operating expenses, which is positive. However, the company continues to operate at a loss, and its cash runway extends only into 2026, suggesting a future capital raise will be necessary. The positive clinical updates outweigh the ongoing burn rate for a clinical-stage biotech.

Positives

• DA-1726 Phase 1 data showed strong safety and tolerability, up to 6.3% mean body-weight reduction, and up to 3.9 inches waist circumference reduction.
• DA-1726 PK data supports once-weekly dosing with an 80-hour half-life.
• DA-1726 achieved comparable weight loss to pemvidutide with superior lipid-lowering efficacy in a diet-induced obesity (DIO) mouse model.
• Vanoglipel (DA-1241) Phase 2a results demonstrated meaningful reductions in liver fat, inflammation, and fibrosis for MASH.
• Research and Development (R&D) expenses decreased by $2.6 million in Q3 2025 compared to Q3 2024, and by $10.9 million for the nine months ended September 30, 2025, compared to the same period in 2024.
• General and Administrative (G&A) expenses decreased by $0.2 million in Q3 2025 compared to Q3 2024, and by $0.6 million for the nine months ended September 30, 2025, compared to the same period in 2024.
• Net loss significantly improved to $3.4 million in Q3 2025 from $5.7 million in Q3 2024, and to $11.0 million for the nine months ended September 30, 2025, from $22.4 million for the same period in 2024.
• Cash position of $14.3 million is expected to fund operations into 2026.

Negatives

• Total Other Income decreased by $0.5 million in Q3 2025 compared to Q3 2024, primarily due to lower interest income and a loss from the change in fair value of warrant liabilities.
• Total Other Income decreased by $0.2 million for the nine months ended September 30, 2025, compared to the same period in 2024, primarily due to lower interest income.
• The company continues to operate at a net loss, reporting $3.4 million for Q3 2025 and $11.0 million for the nine months ended September 30, 2025.
• Cash balance decreased from $16.0 million as of December 31, 2024, to $14.3 million as of September 30, 2025.

Risks

• Ability to execute on commercial strategy.
• Sufficiency of existing cash on hand to fund operations.
• Timeline for regulatory submissions.
• Ability to obtain regulatory approval through the development steps of current and future product candidates.
• Ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results.
• Cooperation of contract manufacturers, clinical study partners, and others involved in product development.
• Potential negative interactions between product candidates and any other products with which they are combined for treatment.
• Ability to initiate and complete clinical trials on a timely basis.
• Ability to recruit subjects for clinical trials.
• Whether clinical trial results are consistent with pre-clinical and previous clinical trials.
• Impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions.
• Effects of changes in applicable laws or regulations.
• Effects of changes to MetaVia's stock price on the terms of the license agreement and any future fundraising.

Future Outlook

The company expects to report top-line data from the 8-week 48 mg MAD cohort of its DA-1726 Phase 1 clinical trial by year-end 2025. For vanoglipel (DA-1241), an end-of-Phase 2 meeting with the FDA is being scheduled for the first half of 2026 to discuss the next stage of clinical development. The current cash position of $14.3 million is anticipated to fund operations into 2026.

Management Comments

• "During the third quarter and subsequently, we continued to make strong progress advancing our next-generation cardiometabolic portfolio, highlighted by the Phase 1 data for DA-1726 presented just recently at ObesityWeek 2025." Hyung Heon Kim, CEO.
• "These results further reinforce DA-1726s potential as a differentiated dual oxyntomodulin (OXM) analog agonist for the treatment of obesity." Hyung Heon Kim, CEO.
• "As previously reported, the 32 mg cohort demonstrated a strong safety and tolerability profile without the need for titration, along with potentially best-in-class weight loss and waist circumference reduction." Hyung Heon Kim, CEO.
• "Based on these encouraging findings, during the quarter we extended the Phase 1 study to include an 8-week, 48 mg cohort to assess longer-term efficacy, safety, and the non-titrated maximum tolerated dose." Hyung Heon Kim, CEO.
• "We expect to report results from this cohort by year-end, which will help inform the next stage of development and further demonstrate DA-1726s potential as a best-in-class treatment for obesity." Hyung Heon Kim, CEO.
• "With regard to our second asset, vanoglipel (DA-1241), a first-in-class oral GPR119 agonist, the 16-week Phase 2a results demonstrated meaningful reductions in liver fat, inflammation and fibrosis – three key drivers of metabolic dysfunction-associated steatohepatitis (MASH) progression." Hyung Heon Kim, CEO.

Industry Context

MetaVia operates in the highly competitive clinical-stage biotechnology sector, specifically targeting cardiometabolic diseases like obesity and MASH. The development of dual GLP1R/GCGR agonists like DA-1726 is a key trend in obesity treatment, aiming for superior weight loss compared to GLP1R-only agonists. The MASH market also represents a significant unmet medical need, with oral GPR119 agonists like vanoglipel offering a differentiated approach with hepatoprotective and glucose-regulating benefits. The collaboration with an AI-driven drug discovery company (Syntekabio) reflects a broader industry trend towards leveraging AI for drug optimization and target identification.

Comparison to Industry Standards

• DA-1726 demonstrated "potentially best-in-class weight loss and waist circumference reduction" in its Phase 1 trial.
• In a diet-induced obesity (DIO) mouse model, DA-1726 achieved "comparable weight loss to pemvidutide with superior lipid-lowering efficacy." Pemvidutide is a known GLP-1/glucagon receptor dual agonist developed by Altimmune, Inc., indicating a direct comparison to a competitor's advanced candidate.
• Vanoglipel (DA-1241) is described as a "first-in-class oral GPR119 agonist," suggesting a novel mechanism of action compared to existing or pipeline MASH treatments.

Related Party Transactions

• R&D costs included $0.2 million for Q3 2025 and $2.6 million for the nine months ended September 30, 2025, related to investigational drug manufacturing, non-clinical, and preclinical costs incurred under the Shared Services Agreement with Dong-A ST (a related party).
• Related party payable increased to $3.316 million as of September 30, 2025, from $1.472 million as of December 31, 2024.

Stakeholder Impact

• Shareholders: Positive clinical trial results and reduced net loss could increase investor confidence, but the limited cash runway and potential future dilution from a capital raise remain considerations.
• Patients: Promising data for DA-1726 in obesity and vanoglipel in MASH offers hope for new, potentially more effective treatment options for significant health conditions.
• Employees: Continued progress in the pipeline and a clear path for clinical development provide stability and focus.
• Partners (Dong-A ST, Syntekabio): Ongoing collaboration and successful trial progression strengthen partnerships and potential for future joint ventures or licensing agreements.
• Creditors: Reduced operating expenses and a clear cash runway into 2026 provide some financial stability, though the company remains unprofitable.

Next Steps

• Report top-line data from the 8-week 48 mg MAD cohort of DA-1726 Phase 1 clinical trial by year-end 2025.
• Present full data from the vanoglipel Phase 2a trial in a poster at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2025.
• Schedule an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) during the first half of 2026 to discuss the next stage of clinical development for vanoglipel.
• Continue to advance the next-generation cardiometabolic portfolio.

Key Dates

Recommendation

The filing contains very positive clinical data for both lead drug candidates, DA-1726 and vanoglipel, suggesting strong therapeutic potential and "best-in-class" characteristics for DA-1726. The significant reduction in net loss and operating expenses is also a favorable financial development. However, as a clinical-stage biotech, the company remains unprofitable, and its cash runway is limited to "into 2026," indicating a high likelihood of future dilution through a capital raise. While the clinical progress is encouraging, the financial position warrants a "hold" rather than a "buy" until more clarity on long-term funding and further clinical milestones (like the end-of-Phase 2 FDA meeting) are achieved. The stock has significant upside potential if trials continue to succeed, but also considerable risk given the need for future financing and the inherent uncertainties of drug development.

Keywords

MetaVia, MTVA, biotechnology, cardiometabolic diseases, obesity, MASH, DA-1726, vanoglipel, DA-1241, Phase 1 clinical trial, Phase 2a clinical trial, GLP1R agonist, GCGR agonist, GPR119 agonist, weight loss, liver fat reduction, financial results, Q3 2025, SEC filing, clinical-stage, drug development, biopharma